A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

A Randomized, Open-label, Single-dose, Four-sequence, Four -Period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

GL2702 GLARS-NF1 tablet is controlled released formulation which is invented by GL Pharm Tech Corp.

Inclusion Criteria:

• 20~45 years old, Healthy Adult Male Subject
• Body Weight ≥ 50kg and Ideal Body Weight ≤ ±20%

Exclusion Criteria:

• ALT or AST > 1.25 times (Upper Normal Range)
• Total Bilirubin > 1.5 times (Upper Normal Range)
• CPK > 2 times (Upper Normal Range)
• BUN or Creatinine > Normal Range
• Systolic BP > 160mmHg or < 80mmHg, Diastolic BP > 100mmHg or < 50mmHg